Immunotherapy using heat-shock protein preparations of leukemia cells after syngeneic bone marrow transplantation in mice

Blood

Volumn 98, Issue 6, 2001, Pages 1852-1857

  Sato, Kazuya ^a   Torimoto, Yoshihiro ^a   Tamura, Yasuaki ^a   Shindo, Motohiro ^a   Shinzaki, Hitoshi ^a   Hirai, Katsuyuki ^a   Kohgo, Yutaka ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GLYCOPROTEIN GP 96; HEAT SHOCK PROTEIN 70; PEPTIDE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FEMALE; GRAFT REJECTION; IMMUNE RESPONSE; ISOGRAFT; LEUKEMIA CELL; LYMPHOCYTE DEPLETION; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; VACCINATION;

EID: 0035885969     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.6.1852     Document Type: Article

References (35)

1. Przepiorka D, Srivastava PK. Heat shock proteinpeptide complexes as immunotherapy for human cancer. Mol Med Today. 1998;478-484.
2. Fourie AM, Samblrook JF, Gething MJ. Common and divergent peptide binding specificities of HSP70 molecular chaperones. J Biol Chem. 1994;269:30470-30478.
3. Li Z, Srivastava PK. A critical contemplation on the role of heat shock proteins in transfer of antigenic peptides during antigen presentation. Behring Inst. 1994;94:37-47.
4. Nieland TJF, Tan MCA, Monne-van Muijien M, Koning F, Kruisbeek AM, Van Bleek GM. Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein gp96/grp94. Proc Natl Acad Sci U S A. 1996;93:6135-6139.
5. Lammert E, Arnold D, Nijenhuis M, et al. The endoplasmic reticulum-resistant stress protein96 binds peptides translocated by TAP. Eur J Immunol. 1997;27:923-927.
6. Spee P, Neefjes J. TAP-translocated peptides specifically bind proteins in cytoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulum. Eur J Immunol. 1997;27:2441-2449.
7. Srivastava PK, Udono H, Blachere N, Li Z. Heat shock proteins transfer peptide during antigen processing and CTL priming. Immunogenetics. 1994;39:93-98.
8. Srivastava PK, Udono H. Heat shock protein-peptide complexes in cancer immunotherapy. Curr Opin Immunol. 1994;6:728-732.
9. Traversari C, van der Bruggen P, Luescher IF, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med. 1992;176:1453-1457.
10. Gaugler B, van den Eynde B, van der Bruggen P, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes J Exp Med. 1994;179:921-930.
11. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunogenic and therapeutic evaluation of a synthetic peptide vaccine for treatment of patients with metastatic melanoma. Nat Med. 1998;4:321-327.
12. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-332.
13. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science. 1997;278:117-120.
14. Harousseau JL, Attal M, Divine M, et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma. Blood. 1995;85:3077-3085.
15. Antman KH, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol. 1997;15:1870-1879.
16. Brunvand MW, Bensinger WI, Soil E, et al. High-dose fractionated total body-irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow transplantation and peripheral blood stem cells. Bone Marrow Transplant. 1996;18:131-141.
17. Kim KJ, Langevin CK, Merwin RM, Sachs DH, Asfsky R. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol. 1979;122:549-554.
18. Chesebro B, Wehrly K, Chesebro K, Portis J. Characterization of Ia8 antigen, Thy-1.2 antigen, complement receptors, and virus production in a group of murine virus-induced leukemia cell lines. J Immunol. 1976;117:1267-1274.
19. Corbett TH, Griswold DP Jr, Robert BJ, Peckhan JC, Schabel FM Jr. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assay, with a note on carcinogen structure. Cancer Res. 1975;35:2434-2439.
20. Srivastava PK. Purification of heat shock protein-peptide complexes for use in vaccination against cancers and intracellular pathogens. Methods Enzymol. 1997;12:165-171.
21. Obayashi T, Tamura H, Tanaka S, et al. A new chromogenic endotoxin-specific assay using recombined limulus coagulation enzymes and its clinical applications. Clin Chim Acta. 1985;149:55-65.
22. Tschopp J, Nabhplz M. Perforin-mediated target cell lysis by cytolytic T lymphocytes. Ann Rev Immunol. 1990;8:279-302.
23. Uharek L, Glass B, Gaska T, Gassmann W, Loeftier H, Mueller-Ruchholts W. Influence of donor lymphocytes on the incidence of primary graft failure after allogeneic bone marrow transplantation in a murine model. Br J Haematol. 1994;88:79-87.
24. Glass B, Uharek L, Zeis M, et al. Allogeneic peripheral blood progenitor cell transplantation in a murine model: evidence for an improved graft-versus-leukemia effect. Blood. 1997;90:1694- 1700.
25. Frei E III, Freireich EJ. Progress and perspectives in the chemotherapy of acute leukemia. Adv Chemother. 1965;2:269-298.
26. + T cells in vivo. Proc Natl Acad Sci U S A. 1994;91:3077-3081.
27. Udono H, Srivastava PK. Heat-shock protein70-associated peptides elicit specific cancer immunity. J Exp Med. 1993;178:1391-1396.
28. Udono H, Srivastava PK. Comparison of tumor-specific immunogenetics of stress-induced proteins gp96, HSP90, and HSP70. J Immunol. 1994;152:5398-5403.
29. Glass B, Uharek L, Zeis M, Loeffler H, MuellerRuchholtz W, Gassmann W. Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells. Br J Haematol. 1996;93:412-420.
30. Oehen S, Brduscha-Riem K. Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. J Immunol. 1998;161:5338-5346.
31. Hu HM, Urba WJ, Fox BA. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J Immunol. 1998;161:3033-3041.
32. Abdul-Hai A, Or R, Stavin S, et al. Stimulation of immune reconstitution by interleukin-7 after syngeneic bone marrow transplantation in mice. Exp Hematol. 1996;24:1416-1422.
33. Asea A, Kraeft SK, Kurt-Jones EA, et al. HSP70 stimulates cytokine production through a CD14-dependent pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med. 2000;6:435-442.
34. Roskrow MA, Dilloo D, Suzuki N, Zhong W, Rooney CM, Brenner MK. Autoimmune disease induced by dendritic cell immunization against leukemia. Leuk Res. 1999;23:549-557.
35. Janetzki S, Palla D, Rosenhauer V, Lochs H, Lewis JJ, Srivastava PK. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer. 2000;88:232-238.